Oppenheimer raised the firm's price target on Pennant Group to $40 from $37 and keeps an Outperform rating on the shares following the company's earnings reported. The firm argues that the strong results reflect the continued integration of the AMED/UNH deal, which is on-track to be completed by the end of Q3 2026. While the results were solid, Pennant is holding off on updating guidance until it sees one more quarter. With that said, management is now pointing toward the top-end of its prior 2026 guidance ranges, adds Oppenheimer.
